Search results
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 21 minutes agoFlamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) PR Newswire LEUVEN, Belgium and STRASBOURG, ...
Larimar Therapeutics director buys $500k in company stock By Investing.com
Investing.com· 2 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR) Director Thomas Edward Hamilton has recently made a...
Iterum Therapeutics’ (ITRM) “Buy” Rating Reiterated at HC Wainwright
ETF DAILY NEWS· 12 hours agoIterum Therapeutics (NASDAQ:ITRM – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on ...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 4 hours agoOn Sunday, Intellia Therapeutics (Nasdaq: NTLA) said that its experimental gene-editing treatment...
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
Zacks via Yahoo Finance· 5 days agoAcrivon Therapeutics ACRV is a precision oncology company that has seen significant progress across...
Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $40.22
ETF DAILY NEWS· 15 hours agoDenali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has received an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com ...
Exploration capital buys fresh tracks therapeutics shares worth $9,579 By Investing.com
Investing.com· 2 days agoExploration Capital, LLC, a significant shareholder in Fresh Tracks Therapeutics, Inc....
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC...
The Parsons Sun· 17 hours agoGenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS ...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in...
Benzinga· 3 hours ago- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support
We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A...
Simply Wall St. via Yahoo Finance· 4 days agoKey Insights Sangamo Therapeutics will host its Annual General Meeting on 4th of June Salary of...
